利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.008 秒)

    AN MRNA CANCER VACCINE ENCODING HUMAN GM-CSF FUSED TO MULTIPLE TANDEM EPITOPES
    1.
    发明申请
    AN MRNA CANCER VACCINE ENCODING HUMAN GM-CSF FUSED TO MULTIPLE TANDEM EPITOPES 审中-公开

    公开(公告)号：WO2018156106A1

    公开(公告)日：2018-08-30

    申请号：PCT/US2017/018771

    申请日：2017-02-22

    申请人： DING, Enyu

    发明人： DING, Enyu

    IPC分类号： A61K39/00 ,  A61P35/00 ,  A61K47/48 ,  A61K48/00

    摘要： The present invention provides an mRNA cancer vaccine encoding human GM-CSF fused to multiple tandem epitopes. pVec-GM-CSF-hTes encoding human GM-CSF fused to three tandem hTERT epitopes, pVec-GMKE encoding human GM-CSF fused to three tandem epitopes respectively from MUC1, Kras and EGFR, pVec-hIL-12 encoding human interleukin-12 are respectively constructed, and used as templates for generating the corresponding in vitro transcribed mRNAs, which are mixed together as an mRNA cancer vaccine. This mRNA cancer vaccine contains human GM-CSF used as an immune adjuvant, multiple tandem epitopes constituting as multi-epitope cancer antigens and hIL-12 used to enhance the immunotherapeutic effects.

    A UNIVERSAL NUCLEIC ACID DRUG VECTOR ENHANCING MRNA STABILITY AND TRANSLATABILITY
    2.
    发明申请
    A UNIVERSAL NUCLEIC ACID DRUG VECTOR ENHANCING MRNA STABILITY AND TRANSLATABILITY 审中-公开
    普遍的核酸药物载体增强MRNA的稳定性和可转换性

    公开(公告)号：WO2017123242A1

    公开(公告)日：2017-07-20

    申请号：PCT/US2016/013588

    申请日：2016-01-15

    申请人： DING, Enyu

    发明人： DING, Enyu

    IPC分类号： C12N15/64 ,  C12N15/63 ,  A61K48/00

    CPC分类号： C12N15/85 ,  A61K48/00 ,  C07K14/535 ,  C12N15/64 ,  C12N15/67 ,  C12N2800/107 ,  C12N2830/50 ,  C12N2830/60

    摘要： In order to improve mRNA stability and translatabihty in cells, the present invention provides pVec that is obtained through in turn constructing pcDNA3.1 -5'UTR-MCS-3'UTR- pA, pcDNA3.1 -5'UTR-MCS (no Spel, BamHI/EcoRI)-3'UTR-pA, pVecO-5'UTR-MCS (no Spel, BamHI/EcoRI)-3'UTR-pA, achieving pVecl -5'UTR-MCS (no Spel, BamHI/EcoRI)- 3'UTR-pA, referred to as pVec. It contains CMV enhancer/promoter, T7 promoter, 5'UTR, MCS, 3'UTR, poly A (120A)-TTATT, BGH poly (A) signal, kanamycin resistance gene and pUC origin, etc., and is mainly characterized in being able to enhance the stability and translatabihty of the in vitro transcribed mRNA in cells. pVec can be both a DNA vaccine or drug vector and an mRNA vaccine or drug vector. The present invention also provides the construction of pVec-GM-CSF, pVec-hlL-12 and pVAX1 -hlL-12, which are as application examples of evaluating the benefits of pVec.

    摘要翻译： 为了提高mRNA稳定性和细胞中的可转移性，本发明提供了通过依次构建pcDNA3.1 -5'UTR-MCS-3'UTR-pA，pcDNA3.1 5'-UTR-MCS（no SpeI，BamHI / EcoRI）-3'UTR-pA，pVecO-5'UTR-MCS（noSpe1，BamHI / EcoRI）-3'UTR-pA，实现pVec15'UTR- MCS（no SpeI，BamHI / EcoRI） - 3'UTR-pA，称为pVec。 它含有CMV增强子/启动子，T7启动子，5'UTR，MCS，3'UTR，polyA（120A）-TTATT，BGH poly（A）信号，卡那霉素抗性基因和pUC起点等，其主要特征在于 能够增强细胞中体外转录mRNA的稳定性和可转译性。 pVec可以是DNA疫苗或药物载体，也可以是mRNA疫苗或药物载体。 本发明还提供了作为评估pVec益处的应用实例的pVec-GM-CSF，pVec-hIL-12和pVAX1-hIL-12的构建。